SL-164
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H12Cl2N2O |
Molar mass | 319.19 g·mol−1 |
3D model (JSmol) | |
| |
|
SL-164, also known as dicloqualone or DCQ, is an analogue of methaqualone developed in the late 1960s by a team at Sumitomo.[1] SL-164 has similar sedative, hypnotic[2] and properties to the parent compound, but was never marketed for clinical use, due to higher risk of convulsions. Like other 4-substituted analogues, like methylmethaqualone, SL-164 may cause seizures.[3]
References
[edit]- ^ US 3651230, "Compositions And Methods For Tranquilizing With Substituted 3-Phenyl-4-Quinazolinone Derivatives"
- ^ Saito C, Sakai S, Yukawa Y, Yamamoto H, Takagi H (December 1969). "Pharmacological studies on 2-methyl-3(2'-methyl-4'-chlorophenyl)-5-chloro-4[H)-quinazolinone (SL-164)". Arzneimittel-Forschung. 19 (12): 1945–9. PMID 4985336.
- ^ Boltze KH, Dell HD, Lehwald H, Lorenz D, Rueberg-Schweer M (August 1963). "[Substituted 4-Quinazolinone Derivatives As Hypnotics]". Arzneimittel-Forschung (in German). 13: 688–701. PMID 14085923.
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
Hidden categories: